Buprenorphine Improved Resistant Depression Outcomes
the Psychiatry Advisor take:
Jordan F. Karp, MD, of the University of Pittsburgh School of Medicine in Pennsylvania, and colleagues assessed whether buprenorphine improved symptoms in 50 patients with treatment-resistant depression (TRD aged 50 years and older. Participants were prescribed titrated doses of buprenorphine (0.2–1.6 mg/d) during an eight-week period.
Changes in depression, anxiety, sleep, positive and negative effect, and quality of life were assessed. The Montgomery-Asberg Depression Rating Scale (MADRS) served as the main outcome measure.
Mean depression score (MADRS) at baseline was 27.0 versus 9.5 at week eight. A sharp decline in depression severity occurred during the first three weeks of buprenorphine exposure (mean change = −15.0), the researchers reported in the Journal of Clinical Psychiatry.
In addition, depression-specific items measuring pessimism and sadness indicated improvement during exposure, supporting a true antidepressant effect. Also, executive function and learning improved during treatment.
“Low-dose buprenorphine may be a novel-mechanism medication that provides a rapid and sustained improvement for older adults with TRD,” the researchers concluded.
Buprenorphine May Benefit Patients With Treatment-Resistant Depression
The objective of the study is to describe the clinical effect and safety of low-dose buprenorphine, a κ-opioid receptor antagonist, for treatment-resistant depression (TRD) in midlife and older adults.
Method: In an 8-week open-label study, buprenorphine was prescribed for 15 adults aged 50 years or older with TRD, diagnosed with the Structured Clinical Interview for DSM-IV, between June 2010 and June 2011. The titrated dose of buprenorphine ranged from 0.2–1.6 mg/d.
We assessed clinical change in depression, anxiety, sleep, positive and negative affect, and quality of life. The Montgomery-Asberg Depression Rating scale (MADRS) served as the main outcome measure. Tolerability was assessed by documenting side effects and change in vital signs, weight, and cognitive function. Clinical response durability was assessed 8 weeks after discontinuation of buprenorphine.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- FDA Approves Schizophrenia Medication With Digital Ingestion Sensor
- Increased Depression Severity Following Childhood Exposure to Adversity, Risk
- Suboptimal Neuromotor Development Related to Genetic Risk for Schizophrenia
- No Association Between Comorbid Anxiety Disorders, Suicide Attempts
- Cannabidiol Concentration, Labeling Varies Widely in Products Sold Online
- Maintenance rTMS for Treatment-Resistant Depression
- Eye Movement Desensitization and Reprocessing Reduces PTSD Symptoms
- Micronutrients Improve Some Symptoms of ADHD
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Long-Acting Injectable Antipsychotics Delay Schizophrenia Relapse
- Frequent Migraines Increase Severity of Anxiety, Depression
- Abnormal MRI and CSF Findings May Predict Risk for Alzheimer's Dementia
- Genetic Link Between Obesity Traits, Depression With Atypical Features
- Improved Outcomes for Patients Treated by Own PCP During Hospital Stay
- Patients With Excessive Daytime Sleepiness May Benefit From Sodium Oxybate